Table 1 General information on anti-cancer TKI
Tyrosine kinase inhibitor (INN) | Branded name | Market Authorization Holder (MAH) | Target tyrosine kinases | Indication(s) | European birth date | CMA | Orphan designation |
|---|---|---|---|---|---|---|---|
Bosutinib | Bosulif® | Pfizer | BCR-ABL,SRC | Patients with CML for which Imatinib, Nilotinib, and Dasatinib are not appropriate | 27th March 2013 | Yes | CML |
Dasatinib | Sprycel® | Bristol-Myers Squibb | BCR-ABL | CML | 23th December 2005 | No | CML, ALL |
Erlotinib | Tarceva® | Hoffman-La Roche | EGFR | NSCLC, pancreatic cancer | 19th September 2005 | No | No |
Gefitinib | Iressa® | Astra Zeneca | EGFR | NSCLC in carriers of activating EGFR-mutations | 24th June 2010 | No | No |
Imatinib | Glivec® | Novartis | BCR-ABL, KIT, PDGFR-A, PDGFR-B | CML, GIST, BCR-ABL- positive ALL, dermatofibrosarcoma protuberans, myeloproliferative neoplasms, hypereosinophilic syndromes | 7th of November 2001 | No | Expired and withdrawn |
Lapatinib | Tyverb® | Glaxo Smith Kline | ERBB2 (HER-2) | HER-2 positive breast cancer | 10th June 2008 | Yes | No |
Nilotinib1 | Tasigna® | Novartis | BCR-ABL, KIT,PDGFR-A, PDGFR-B | CML | 19th November 2007 | No | CML |
Pazopanib | Votrient® | Glaxo Smith Kline | VEGFR, PDGFR, KIT | Renal cell carcinoma, STS | 14th June 2010 | No | Withdrawn |
Ponatinib2 | Iclusig® | Ariad | BCR-ABL | Patients with CML for which Imatinib, Nilotinib, and Dasatinib are not appropriate (or patients carrying a T315I single-point-mutation) | 1st July 2013 | CML, ALL | |
Sorafenib | Nexavar® | Bayer | VEGFR-2,VEGFR-3 | Renal cell carcinoma, hepatocellular carcinoma | 19th July 2006 | No | Renal cell carcinoma, Hepatocellular carcinoma |
Sunitinib | Sutent® | Pfizer | VEGFR 1-3, PDGFR-A, PDGFR-B; KIT, FLT3 | Renal cell carcinoma, GIST, pNET | 19th July 2006 | Initially, then full approval | Withdrawn |